Erythropoiesis is the process by which your body manufactures red blood cells, and it is astonishingly prolific: the bone marrow churns out roughly two million new red blood cells every second just to keep up with normal daily losses. The process involves a cascade of cell divisions and physical transformations, starting from stem cells deep in the marrow and ending with the flexible, oxygen-carrying discs that circulate through your bloodstream. What makes erythropoiesis especially interesting is how tightly it is regulated, how dramatically it can ramp up under stress, and how many things can go wrong along the way.
From Stem Cell to Red Blood Cell
Red blood cells begin their life as multipotent stem cells in the bone marrow. These stem cells can become many different blood cell types, but once they commit to the red cell lineage, they pass through a series of increasingly specialized progenitor stages. The earliest committed red cell progenitors are called BFU-E (burst-forming unit, erythroid), which then mature into CFU-E (colony-forming unit, erythroid). From CFU-E onward, the hormone erythropoietin drives rapid rounds of cell division and maturation, pushing progenitors through stages recognizable under the microscope: proerythroblasts, basophilic erythroblasts, polychromatic erythroblasts, and finally orthochromatic erythroblasts.1PubMed Central. From stem cell to erythroblast: regulation of red cell production at multiple levels by multiple hormones During chronic anemia or inflammation, the body also expands the earlier BFU-E pool using glucocorticoids and other signaling molecules, effectively widening the pipeline when demand for red cells rises.
At each step, the cell shrinks, accumulates hemoglobin (the protein that carries oxygen), and undergoes changes that would strike most people as extreme. The most dramatic is enucleation: the cell physically pushes out its own nucleus. The result is a reticulocyte, a young red blood cell that still contains some residual organelles. Over the next day or two, the reticulocyte clears out its remaining mitochondria and ribosomes, becoming the mature red blood cell, or erythrocyte, that will circulate for about 120 days.
The Nursery Inside Your Bones
Red blood cells do not mature in isolation. Inside the bone marrow, developing red cells cluster around a large central macrophage, forming a structure called an erythroblastic island. Picture a flower: the macrophage is the center, and the surrounding ring of maturing red cell precursors are the petals. The macrophage extends arm-like projections to cradle the developing cells, and this physical contact is essential for both early and late stages of red cell maturation.2PubMed Central. The erythroblastic island
These islands serve several purposes. The central macrophage supplies iron to the developing red cells, which need enormous amounts of it to build hemoglobin. It also engulfs and digests the nuclei that erythroblasts eject during enucleation, keeping the marrow tidy. And the macrophage provides survival signals. When researchers disrupt the adhesion molecule that holds erythroblastic islands together, red cell production in the bone marrow suffers.3Blood. Maea expressed by macrophages, but not erythroblasts, maintains postnatal murine bone marrow erythroblastic islands These islands were first described over sixty years ago, yet researchers continue to uncover new details about how the macrophage-erythroblast partnership works.4PubMed Central. Erythroblastic Island Macrophages Shape Normal Erythropoiesis and Drive Associated Disorders in Erythroid Hematopoietic Diseases
Losing the Nucleus and Everything Else
Most of your cells guard their nucleus jealously, so the fact that red blood cells throw theirs away is worth pausing on. Enucleation is not a passive event. The cell’s internal skeleton reorganizes, chromatin condenses tightly, and the nucleus migrates to one side of the cell. At the boundary between nucleus and cytoplasm, a belt of protein machinery pinches the nucleus out, almost like a budding process. The interaction with that central macrophage in the erythroblastic island helps facilitate the whole thing.5PubMed Central. From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals Enucleation involves coordinated protein sorting, vesicle trafficking, cytoskeletal remodeling, and careful regulation of cell-death pathways, all happening simultaneously.6PubMed Central. New insights into the mechanisms of red blood cell enucleation: From basics to clinical applications
After the nucleus is gone, the young reticulocyte still has mitochondria, ribosomes, and other organelles to dispose of. Clearing the mitochondria turns out to rely on autophagy, the same recycling machinery cells use to digest damaged components in other contexts. Studies in mice have shown that genetic disruption of autophagy pathways delays mitochondrial clearance from reticulocytes, confirming that this housekeeping mechanism is critical for producing fully mature red blood cells.7PubMed Central. Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation Why strip out all of these organelles? Without a nucleus, the cell cannot divide or repair itself, but it gains a biconcave disc shape that is optimally flexible for squeezing through tiny capillaries. Without mitochondria consuming oxygen, the red blood cell becomes a pure delivery vehicle: it carries oxygen without using any of it.
The Oxygen-Sensing Hormone That Runs the Show
Erythropoietin, commonly called EPO, is the master regulator of red blood cell production. It is a hormone produced mainly by specialized cells in the kidneys. When blood oxygen levels drop, whether from blood loss, lung disease, or simply moving to a higher altitude, an oxygen-sensing mechanism in these kidney cells detects the shortfall and ramps up EPO production. EPO then travels through the bloodstream to the bone marrow, where it binds to receptors on red cell progenitors and promotes their survival, proliferation, and maturation.8PubMed Central. Erythropoietin regulation of red blood cell production: from bench to bedside and back
The oxygen-sensing system relies on a family of proteins called hypoxia-inducible factors, or HIFs. Under normal oxygen levels, HIF is continuously broken down by enzymes called prolyl hydroxylases. When oxygen drops, those enzymes slow down, HIF accumulates, and EPO gene expression surges. This discovery was significant enough to earn the 2019 Nobel Prize in Physiology or Medicine. It has also opened the door to a new class of drugs: prolyl hydroxylase inhibitors, which stabilize HIF and boost the body’s own EPO production. Clinical trials have shown promising results in treating anemia caused by chronic kidney disease, where damaged kidneys cannot produce enough EPO on their own.9PubMed. Physiology and pathophysiology of renal erythropoietin-producing cells
Built into the EPO signaling pathway are negative feedback loops that prevent overproduction. When EPO binds its receptor and activates downstream signaling, the same pathways simultaneously trigger suppressive signals that eventually dial things down. This self-limiting design keeps the system from overshooting and producing too many red blood cells under normal conditions.
Iron, Hepcidin, and a Hormone You Have Probably Never Heard Of
Iron is the essential ingredient in hemoglobin. Each hemoglobin molecule contains four iron atoms, and each red blood cell contains about 270 million hemoglobin molecules, so the iron demand during active erythropoiesis is enormous. The body tightly controls iron availability through a liver-produced hormone called hepcidin, which acts as a gatekeeper: when hepcidin levels are high, iron absorption from the gut and iron release from storage sites slow down; when hepcidin drops, iron flows more freely.
The link between red blood cell production and iron supply was clarified by the discovery of erythroferrone, or ERFE. When erythropoiesis ramps up, developing red cells in the marrow produce ERFE in response to EPO stimulation. ERFE then suppresses hepcidin, effectively telling the liver to release more iron into the bloodstream so the marrow can use it.10Nature Genetics. Identification of erythroferrone as an erythroid regulator of iron metabolism In mice lacking ERFE, hepcidin does not drop quickly enough after blood loss, and recovery from anemia is delayed.
This system can become a liability in diseases like beta-thalassemia, where erythropoiesis is massively expanded but ineffective: huge numbers of red cell precursors die before maturing. Those dying precursors still pump out ERFE, which chronically suppresses hepcidin and leads to dangerous iron overload even without blood transfusions. In a mouse model of thalassemia, eliminating ERFE restored normal hepcidin levels and significantly reduced iron accumulation in the liver and spleen.11Blood. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia
What Your Diet Has to Do with It
Iron gets the most attention, but erythropoiesis also depends heavily on folate and vitamin B12. Both nutrients are required to synthesize the DNA building blocks that dividing red cell precursors need. When either is deficient, DNA replication stalls, the developing red cells grow abnormally large (because they keep accumulating cytoplasm without dividing properly), and many of them die in the marrow before ever reaching the bloodstream. The result is a type of anemia characterized by abnormally large red blood cells, historically called megaloblastic anemia.12PubMed. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron
This is why certain dietary patterns can cause anemia even when overall calorie intake is adequate. Strict vegans are at risk for B12 deficiency because the vitamin occurs naturally almost exclusively in animal products. Folate deficiency can result from poor vegetable intake or from medications that interfere with folate metabolism. And iron deficiency, the most common nutritional deficiency worldwide, directly limits hemoglobin production. All three nutrients converge on the same process, and a shortage of any one of them can bottleneck the entire assembly line.
Steady State Versus Emergency Mode
Under normal conditions, erythropoiesis hums along in the bone marrow, replacing the roughly one percent of circulating red cells that are cleared from the bloodstream each day. This is steady-state erythropoiesis. But when the body faces acute blood loss, severe infection, or other stressors, it can shift into a qualitatively different mode called stress erythropoiesis.
Stress erythropoiesis does not simply mean “more of the same.” It relies on different progenitor cells and distinct signaling pathways, and in adults it can activate sites outside the bone marrow, particularly the spleen and liver.13PubMed Central. Microenvironmental dynamics in steady-state and stress erythropoiesis In mice, the spleen is a major stress erythropoiesis site; in humans, the spleen and liver can also contribute, though the bone marrow still does the bulk of the work. This extramedullary production (literally “outside the marrow”) is why people with chronic hemolytic anemias can develop enlarged spleens: the organ is working overtime to produce red cells.
Glucocorticoids play an important role during stress erythropoiesis by expanding the pool of early progenitors, effectively giving EPO more raw material to work with.14PubMed Central. From stem cell to erythroblast: regulation of red cell production at multiple levels by multiple hormones This is one reason corticosteroid medications can raise red blood cell counts as a side effect, and why patients under extreme physiological stress sometimes show a bump in their blood counts even without obvious bleeding.
Before You Were Born
Erythropoiesis does not start in the bone marrow. During embryonic development, the first red blood cells are produced in the yolk sac, as early as the third week of gestation. These primitive red cells are different from the adult version: they are larger, they retain their nuclei, and they carry embryonic forms of hemoglobin designed for the unique oxygen-delivery challenges of early fetal life.
Around six weeks of development, red cell production shifts from the yolk sac to the fetal liver, and the hemoglobin switches from embryonic varieties to fetal hemoglobin, which has a higher affinity for oxygen than adult hemoglobin. This gives the fetus an advantage in extracting oxygen from maternal blood across the placenta. Researchers studying human embryonic stem cells have shown that these hemoglobin switches can be recapitulated in the lab, with yolk-sac-like cells and fetal-liver-like cells appearing in sequence, closely mimicking natural development.15PubMed Central. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells Studies of human yolk sacs and fetal livers at different developmental stages have confirmed that these switches in globin type track closely with where red cells are being made.16PubMed Central. Embryonic—-Fetal Hb switch in humans: studies on erythroid bursts generated by embryonic progenitors from yolk sac and liver
In the third trimester, the bone marrow gradually takes over as the primary site, and after birth, fetal hemoglobin is slowly replaced by adult hemoglobin over the first several months of life. This transition matters clinically: diseases like sickle cell disease and beta-thalassemia, which affect adult hemoglobin, often do not become symptomatic until fetal hemoglobin levels decline in infancy. Therapies that reactivate fetal hemoglobin production, such as the drug hydroxyurea, exploit this biology.
When Erythropoiesis Goes Wrong
Disorders of erythropoiesis fall broadly into two categories: too few red blood cells (anemia) and too many (polycythemia). The causes range from nutritional deficiencies and kidney disease to genetic mutations and bone marrow cancers.
In ineffective erythropoiesis, the marrow produces large numbers of red cell precursors, but they die before maturing. Beta-thalassemia and myelodysplastic syndromes are classic examples. Patients with these conditions are often anemic despite having hypercellular bone marrows packed with developing red cells. The iron overload problem described earlier compounds the damage, and many patients require regular blood transfusions.17PubMed. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron
On the opposite end, polycythemia vera is a condition in which a mutation in the JAK2 gene makes red cell progenitors hypersensitive to EPO. The most common mutation, called JAK2 V617F, causes progenitors to proliferate even at very low EPO levels. Progenitors carrying two copies of the mutation can grow entirely independently of EPO.18PubMed. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera The result is a dangerously high red blood cell count that thickens the blood and raises the risk of blood clots, stroke, and heart attack. Treatment typically involves periodic phlebotomy (drawing blood to lower the red cell count) and sometimes medications that suppress the overactive marrow.
High-Altitude Adaptation and the Tibetan Exception
Move to a high-altitude city and your body will respond predictably: EPO production rises, more red blood cells are made, and your hemoglobin concentration climbs to compensate for thinner air. This is textbook acclimatization. But populations that have lived at extreme altitudes for thousands of years tell a more nuanced story.
Tibetans, who have inhabited the Himalayan plateau for millennia, do not show the elevated hemoglobin levels you might expect. Studies comparing Tibetans, long-term Han Chinese residents at high altitude, and Han newcomers have found that Tibetans and acclimatized Han populations actually have hemoglobin and red cell counts comparable to people living at sea level, while recent Han arrivals show the expected increases.19PubMed. Investigation of the differences between the Tibetan and Han populations in the hemoglobin-oxygen affinity of red blood cells and in the adaptation to high-altitude environments Tibetans appear to have evolved adaptations that improve oxygen delivery without relying on excess red blood cell production, which avoids the risks of blood thickening. Genetic studies have shown that blood characteristics like hematocrit and red cell size differ between Tibetans and Han Chinese at the same altitude, pointing to genetic rather than purely environmental differences.20PubMed Central. Genetic and immune changes in Tibetan high-altitude populations contribute to biological adaptation to hypoxia
This is a reminder that the “make more red blood cells” response to low oxygen is the quick-and-dirty fix, not the only solution. Over evolutionary time, populations under chronic hypoxic pressure found ways to optimize oxygen delivery at the level of hemoglobin affinity, capillary density, and metabolic efficiency rather than simply cranking out more red cells.
How Old Red Blood Cells Are Retired
After roughly 120 days in circulation, aging red blood cells are pulled from the bloodstream and recycled. The spleen is the primary site for this clearance, though the liver also participates. Macrophages in these organs recognize old red cells through several signals: the cells become less flexible, their membranes undergo chemical changes, and they display surface markers that flag them for removal.
One of those markers involves a protein called CD47, which acts as a “don’t eat me” signal to macrophages. Research in mice has shown that CD47 expression drops by about 30 percent over a red blood cell’s lifespan. The oldest cells have the lowest CD47 levels, making them more susceptible to macrophage engulfment. When researchers depleted macrophages, senescent red cells accumulated in the blood and spleen, confirming that active macrophage surveillance is essential for clearing worn-out cells.21PubMed Central. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation
Once a macrophage engulfs an old red cell, it breaks down the hemoglobin, recycles the iron back into the circulation (where it is picked up by a transport protein and delivered back to the marrow), and converts the heme portion into bilirubin. That bilirubin is what gives bruises their yellowish tinge as they heal and, in higher quantities, causes the jaundice seen in newborns or patients with hemolytic anemias.
Growing Red Blood Cells in a Lab
The idea of manufacturing red blood cells from stem cells has been a goal for transfusion medicine for years. In principle, unlimited donor-independent red cells could solve chronic blood shortages and reduce transfusion reactions. Researchers have successfully produced functional red blood cells from human stem cells in the lab, and small-scale transfusion trials have been conducted.
The major bottleneck is not biology but engineering. Current lab production methods are two-dimensional, limited in scale, and expensive. Scaling up to the quantities needed for a single transfusion unit, let alone a national blood supply, requires a shift to large-scale three-dimensional bioreactor systems. Beyond that, the entire production process would need to become at least five times more cost-efficient to compete with conventional blood donation.22PubMed. Large-scale production of red blood cells from stem cells: what are the technical challenges ahead? Enucleation efficiency is another challenge: getting lab-grown red cell precursors to eject their nuclei at rates matching the near-perfect efficiency of the bone marrow remains an active area of research.
Why Only Mammals Bother Ejecting the Nucleus
If you have ever looked at a blood smear from a frog, a fish, or a bird, you would notice something conspicuous: their red blood cells still have nuclei. Among vertebrates, only mammals produce enucleated red blood cells. The conventional explanation has been that removing the nucleus allows the cell to pack more hemoglobin into a smaller, more flexible package, improving oxygen transport efficiency.
When researchers compared red blood cell characteristics across birds and mammals using statistical methods that account for evolutionary relatedness, they found no difference in hemoglobin concentration between the two groups. Birds had somewhat larger red cells by conventional measures, but that difference disappeared after correcting for phylogeny.23American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. Revisiting the question of nucleated versus enucleated erythrocytes in birds and mammals This complicates the simple narrative that enucleation evolved to boost oxygen-carrying capacity. Birds manage impressive feats of aerobic endurance, including high-altitude migration, with nucleated red blood cells. The real advantages of mammalian enucleation may have more to do with the increased deformability of the cell, allowing it to navigate capillaries that are narrower than the cell itself, or with other metabolic trade-offs that remain poorly understood.
The Gene That Made Modern Treatment Possible
For most of the twentieth century, erythropoietin could only be obtained by laboriously purifying it from the urine of anemic patients. Quantities were tiny and the product was impure. That changed in 1985, when researchers successfully cloned the human erythropoietin gene. They identified its structure: five coding segments separated by four intervening sequences, encoding a small signal peptide and a 166-amino-acid mature protein. When they inserted the gene into hamster ovary cells, those cells produced EPO that was biologically active both in cell culture and in living animals.24PubMed Central. Cloning and expression of the human erythropoietin gene
This breakthrough made recombinant EPO possible. Within a few years, synthetic EPO entered clinical use, transforming the treatment of anemia in patients with chronic kidney disease and cancer. It also, infamously, found its way into endurance sports as a performance-enhancing drug. The synthetic version is chemically identical to the natural hormone, which initially made detection difficult, though anti-doping authorities have since developed tests based on subtle differences in the sugar molecules attached to the protein. Patients on synthetic EPO sometimes require more blood pressure medications during treatment, a side effect that researchers continue to study.25PLoS One. Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients The relationship between EPO therapy and blood pressure is complex: in one large study of pre-dialysis patients, those receiving EPO-stimulating agents used more blood pressure medications than those who did not, even though their blood pressure readings were not dramatically different.